^
    Back
    Association details:
    Biomarker:PD-L1 underexpression
    Cancer:Esophageal Squamous Cell Carcinoma
    Drug:Loqtorzi (toripalimab-tpzi) (PD1 inhibitor) +
    Sulanda (surufatinib) (VEGFR inhibitor, VEGFR-2 inhibitor, CSF-1R inhibitor, FGFR1 inhibitor, VEGFR-1 inhibitor, VEGFR-3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR-I 2020
    Title:

    Abstract CT142: A phase I trial of surufatinib plus toripalimab in patients with advanced solid tumor

    Published date:
    04/27/2020
    Excerpt:
    Most patients with negative or low PD-L1 expression achieved PR or CR.
    DOI:
    10.1158/1538-7445.AM2020-CT142
    Trial ID:
    NCT03879057